Catherine Parham, MD, MBA is the Vice President and Head of Global Medical Affairs and is responsible for leading development and execution of the Medical Affairs strategy. She joined Astellas Gene Therapies (formerly Audentes Therapeutics) in August 2020.
Dr. Parham joined Astellas Gene Therapies from Takeda, where she was the Vice President, Global Program Lead in the Plasma Derived Therapies Business Unit, directing development programs focused on therapies to treat patients with rare immunodeficiency diseases. Prior to joining Takeda, Dr. Parham was Vice President, Global Clinical Therapeutic Area Head of Combination Products and Medical Devices at Shire. She led the clinical team responsible for the development of drug delivery systems and diagnostic for therapies to treat rare diseases. Previously Dr. Parham worked at Pfizer, GE Healthcare and Johnson & Johnson in increasing roles of responsibility.
Dr. Parham earned her BS in engineering and literature from MIT, her MD from Boston University and completed her postgraduate medical training at Harvard Beth Israel Deaconess and Tufts Medical Center in Boston, Massachusetts.